Background:To compare the efficacy and safety of monthly administrations of gonadotropin releasing hormone (GnRH) agonists LY01005 and Zoladex ? in Chinese patients with premenopausal breast cancer. Methods:From October 2020 to November 2021, 188 premenopausal breast cancer patients were enrolled in 34 hospitals and randomized 1:1 to receive either LY01005 or Zoladex ? every 28 days for a total of three injections. All patients concomitantly received oral tamoxifen (TAM). The primary efficacy endpoint was cumulative probability of maintaining menopausal level [oestradiol (E2) ≤30 pg/ml] from day 29 to day 85. The second efficacy endpoint included changes in E2, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) compared with the baseline. Pharmacokinetics (PK), pharmacodynamics (PD), and safety were analyzed. The study also evaluated the pharmacokinetic and pharmacodynamic characteristics of LY01005. Results:A total of 188 patients were randomised and 187 patients received either LY01005 or Zoladex ?. Cumulative probabilities of maintaining menopausal level (E2≤30 pg/ml) from day 29 to day 85 were 93.1% for LY01005 and 86.3% for Zoladex ?. The between-group difference was 6.8% (95% CI: -2.3%, 15.9%) and primary efficacy in the LY01005 group was not inferior to that in the Zoladex ? group. Changes in E2, LH, and FSH levels compared with the baseline were equivalent between the two groups (E2: 89.34% to 90.23% vs. 82.11% to 85.02%; LH: 88.89% to 95.52% vs. 89.70% to 97.02%; FSH: 75.36% to 80.85% vs.73.07% to 80.24%, respectively). After three consecutive doses of LY01005, the LH and FSH levels of the subjects showed a transient increase after the first dose, reached a peak on the second day and then started to decrease. The LH and FSH reached a lower level and remained at or below that level until the 85th day. Both treatments were well-tolerated. Conclusion:LY01005 is as effective as Zoladex ? in suppressing E2 to menopausal levels in Chinese patients with premenopausal breast cancer, with a similar safety profile.

Objective To evaluate the efficacy and safety of Qixian Tongluo Formula in the treatment of post-cerebral infarction paralysis with kidney deficiency and blood stasis syndrome,and to preliminarily explore the molecular mechanism of Qixian Tongluo Formula in improving impaired motor function from the perspective of cross-kingdom regulation of Chinese medicine microRNA(miRNA).Methods A pragmatic randomized controlled trial was conducted with 102 patients in the recovery period of post-cerebral infarction paralysis with kidney deficiency and blood stasis syndrome in our hospital.Patients were randomly divided into trial group and control group,with 51 cases in each group.The control group received standard Western medicine standard treatment,while the trial group received Qixian Tongluo Formula in addition to the standard treatment,with one dose per day,boiled in water,and taken warm after breakfast and dinner for a course of 2 months.The disability rate was used as the main efficacy indicator,and the incidence of adverse reactions was used as a safety indicator.miRNA from patient serum and Qixian Tongluo decoction were extracted respectively,and high-throughput sequencing was performed.The two sequences were compared to screen out the cross-kingdom gene transfer of Chinese medicine miRNA.Finally,its target genes of miRNA were predicted,and GO function and KEGG pathway enrichment analysis were carried out.Results A total of 67 patients completed the clinical trial,including 36 cases in the trial group and 31 cases in the control group;The disability rate in the trial group(13.9%)was lower than that in the control group(35.5%)(P<0.05);The incidence of adverse reactions was similar between the trial group(7.69%)and the control group(6.06%)(P>0.05);A total of 9530 Qixian Tongluo decoction miRNA sequences were screened,with 150 potentially involved in cross-kingdom gene transfer,including families such as miR-15 and miR-17;According to the target gene prediction of the top 10 miRNAs in cross-kingdom gene transfer of Chinese medicine,345 overlapping target genes were obtained;GO functional enrichment analysis revealed 16 biological processes,7 cellular components,and 2 molecular functions among the top 25 enriched functions,while KEGG pathway analysis mainly focused on the transforming growth factor-βsignaling pathway,neurotrophin signaling pathway,which are closely related to neural repair and functional recovery processes such as glial scar formation and synaptic plasticity after cerebral ischemia.Conclusion Qixian Tongluo Formula can significantly improve the functional independence level of patients with kidney deficiency and blood stasis syndrome in the recovery period of paralysis after cerebral infarction,offering a safe and effective treatment option for these patients;There were a large number of miRNAs in Qixian Tongluo decoction,some of which could cross-kingdom transferred into the human blood circulation,and promote the recovery of motor function in patients with cerebral infarction through multi-target,multi link and multi pathway gene network regulation.This study provides a new idea for subsequent clinical and basic research.

Objective:To analyze the prevalence and clinical characteristics of pertussis in children with different cough durations.Methods:From January 2021 to October 2022, information on children aged 0-18 years who visited eight hospitals in Shandong Province due to cough was enrolled. Pertussis serological antibody testing and/or nucleic acid testing were performed. The prevalence and clinical characteristics of pertussis were compared among the acute cough group, protracted cough group, and chronic cough group using the χ2 test or Fisher′s exact test. Results:A total of 1 565 children with cough were included in the study, of which 348 (22.24%) were laboratory-confirmed pertussis. There was a significant difference in the laboratory-confirmed rate of pertussis among different cough groups ( χ2=83.424, P<0.001). The confirmation rate of pertussis in the protracted cough group (42.21%) was significantly higher than that in the acute cough group (16.49%, P<0.05) and chronic cough group (19.50%, P<0.05). In each cough group, the age of children was significantly associated with the confirmed rate of pertussis, and the confirmed rate was relatively high in children aged 3 months to <2 years. Pertussis vaccination was significantly associated with the confirmed rate in all groups, and the confirmed rate was higher in unvaccinated children. Among laboratory-confirmed pertussis cases, the incidence of typical symptoms such as paroxysmal cough, whoop, and post-tussive emesis or sleep disturbance was significantly higher than that in the non-confirmed cases. In the protracted and chronic cough groups, the proportion of non-confirmed cases complicated with asthma/cough variant asthma (CVA) was significantly higher than that in pertussis-confirmed cases. Conclusion:There are differences in the confirmation rate of pertussis among children with different cough durations. The confirmation rate is significantly associated with age, vaccination status, and clinical symptoms. Enhancing clinical vigilance against pertussis, conducting early diagnosis, and getting timely and standardized vaccination are crucial for effectively controlling pertussis and preventing outbreaks.

Objective To control the stepwise release of vascular endothelial growth factor A(VEGF-A)within the microcapsules,and to analyze the effects of the microcapsules on cellular angiogenic capability.Methods VEGF-A encapsulated poly(lactic-co-gly-colic acid)(PLGA)microcapsules were prepared using a method combining dual-channel coaxial injection and continuous flow technol-ogy.The release and degradation performance of the microcapsules were characterized using a phosphate-buffered saline(PBS)soaking method.The biocompatibility of the microcapsules was assessed through the CCK-8 method and Calcein-AM/PI staining method.The impact of microcapsule extract on cellular angiogenesis ability was examined by conducting cell scratch assays and tubule formation ex-periments.Results The microcapsules were round in shape,with their particle diameter measuring in the range of hundreds of mi-crometers.Microcapsules with a molecular weight(Mw)-12 ku can release a large amount of VEGF-A in the initial phase,while Mw-30 ku ones had the capacity to provide a stable,long-term,low-dose release of VEGF-A.Microcapsules of Mw-12 ku exhibited outstanding potential for enhancing the healing of cell scratch wounds in the initial phase.Moreover,within the 0-12 day period,the two types of microcapsule extracts significantly enhanced the ability of cells to form tubules in vitro.Conclusion This study successfully regulated the release profile of VEGF-A by adjusting the molecular weight of PLGA,achieving an initial rapid and substantial release of VEGF-A followed by a sustained slow release over time,while maintaining its biological activity throughout the process.

Objectives:To investigate the expression and clinical prognostic implication of secreted frizzled-related protein 4(SFRP4)in the peripheral blood of patients with dilated cardiomyopathy(DCM)and its.Methods:A total of 259 consecutive patients diagnosed with DCM who were admitted to the Cardiac Center of Zhongshan Hospital,Fudan University,from January 2017 to January 2019 were selected for the DCM group.Additionally,84 individuals who underwent health examinations and echocardiography at our hospital during this period,confirmed to be free of cardiovascular diseases,were selected as the control group.Peripheral serum samples were collected from both groups,and serum SFRP4 levels were measured using enzyme-linked immunosorbent assay(ELISA).The correlation between SFRP4 levels and DCM severity,as well as its predictive value for DCM prognosis,were analyzed.Results:Compared to the control group,the serum SFRP4 levels in the DCM group were significantly elevated([28.54±10.25]ng/ml vs.[52.70±19.74]ng/ml,P<0.05).The DCM group was randomly divided into a training set and a validation set in a 2:1 ratio.Multivariate logistic regression analysis in the training set revealed that serum SFRP4 levels were independently associated with all-cause mortality in DCM patients(OR=1.06,95% CI:1.03-1.10,P<0.001).We further evaluated the model's predictive performance with the receiver operating characteristic(ROC)curves(area under curve>0.8),calibration curves,and decision curve analysis,results indicated that the predictive model containing serum SFRP4 levels showed good performance on predicting all-cause mortality in DCM patients.Kaplan-Meier survival curve analysis demonstrated that during a median follow-up of 33.5(11.0,49.0)months,DCM patients with high peripheral blood SFRP4 levels(≥75th percentile)had a significantly higher incidence of all-cause mortality compared to those with low levels(<75th percentile)(28.81% vs.16.57%,P=0.02).Conclusions:The level of SFRP4 in the peripheral blood of DCM patients is significantly elevated,and peripheral serum SFRP4 levels have potential prognostic value for predicting the all-cause mortality in DCM patients.

Objective To control the stepwise release of vascular endothelial growth factor A(VEGF-A)within the microcapsules,and to analyze the effects of the microcapsules on cellular angiogenic capability.Methods VEGF-A encapsulated poly(lactic-co-gly-colic acid)(PLGA)microcapsules were prepared using a method combining dual-channel coaxial injection and continuous flow technol-ogy.The release and degradation performance of the microcapsules were characterized using a phosphate-buffered saline(PBS)soaking method.The biocompatibility of the microcapsules was assessed through the CCK-8 method and Calcein-AM/PI staining method.The impact of microcapsule extract on cellular angiogenesis ability was examined by conducting cell scratch assays and tubule formation ex-periments.Results The microcapsules were round in shape,with their particle diameter measuring in the range of hundreds of mi-crometers.Microcapsules with a molecular weight(Mw)-12 ku can release a large amount of VEGF-A in the initial phase,while Mw-30 ku ones had the capacity to provide a stable,long-term,low-dose release of VEGF-A.Microcapsules of Mw-12 ku exhibited outstanding potential for enhancing the healing of cell scratch wounds in the initial phase.Moreover,within the 0-12 day period,the two types of microcapsule extracts significantly enhanced the ability of cells to form tubules in vitro.Conclusion This study successfully regulated the release profile of VEGF-A by adjusting the molecular weight of PLGA,achieving an initial rapid and substantial release of VEGF-A followed by a sustained slow release over time,while maintaining its biological activity throughout the process.

Thyrotoxic periodic paralysis(TPP) is a rare but potentially life-threatening complication of thyrotoxicosis. TPP secondary to thyrotoxicosis factitia(TF) is exceptionally uncommon. Here, we report the case of a 31-year-old female who developed TF and subsequent TPP after taking laxatives containing unknown ingredients. The patient presented with acute onset of quadriplegia. Laboratory investigations revealed severe hypokalemia(serum potassium 1.47mmol/L), thyrotoxicosis[thyroid stimulating hormone(TSH)<0.005 mIU/L, free thyroxine(FT 4) 30.84 pmol/L, free triiodothyronine(FT 3) 7.71 pmol/L], and a decreased thyroglobulin level(3.08 ng/mL). The patient′s symptoms resolved rapidly following potassium supplementation, and thyroid function gradually normalized after discontinuation of the suspected medication. This case highlights the importance of considering TF in the differential diagnosis of TPP, particularly in patients with a history of unknown medication use. It also underscores the diagnostic value of thyroglobulin measurement in identifying TF and outlines clinical strategies for the management of TF-induced TPP.

Objective To evaluate the efficacy and safety of Qixian Tongluo Formula in the treatment of post-cerebral infarction paralysis with kidney deficiency and blood stasis syndrome,and to preliminarily explore the molecular mechanism of Qixian Tongluo Formula in improving impaired motor function from the perspective of cross-kingdom regulation of Chinese medicine microRNA(miRNA).Methods A pragmatic randomized controlled trial was conducted with 102 patients in the recovery period of post-cerebral infarction paralysis with kidney deficiency and blood stasis syndrome in our hospital.Patients were randomly divided into trial group and control group,with 51 cases in each group.The control group received standard Western medicine standard treatment,while the trial group received Qixian Tongluo Formula in addition to the standard treatment,with one dose per day,boiled in water,and taken warm after breakfast and dinner for a course of 2 months.The disability rate was used as the main efficacy indicator,and the incidence of adverse reactions was used as a safety indicator.miRNA from patient serum and Qixian Tongluo decoction were extracted respectively,and high-throughput sequencing was performed.The two sequences were compared to screen out the cross-kingdom gene transfer of Chinese medicine miRNA.Finally,its target genes of miRNA were predicted,and GO function and KEGG pathway enrichment analysis were carried out.Results A total of 67 patients completed the clinical trial,including 36 cases in the trial group and 31 cases in the control group;The disability rate in the trial group(13.9%)was lower than that in the control group(35.5%)(P<0.05);The incidence of adverse reactions was similar between the trial group(7.69%)and the control group(6.06%)(P>0.05);A total of 9530 Qixian Tongluo decoction miRNA sequences were screened,with 150 potentially involved in cross-kingdom gene transfer,including families such as miR-15 and miR-17;According to the target gene prediction of the top 10 miRNAs in cross-kingdom gene transfer of Chinese medicine,345 overlapping target genes were obtained;GO functional enrichment analysis revealed 16 biological processes,7 cellular components,and 2 molecular functions among the top 25 enriched functions,while KEGG pathway analysis mainly focused on the transforming growth factor-βsignaling pathway,neurotrophin signaling pathway,which are closely related to neural repair and functional recovery processes such as glial scar formation and synaptic plasticity after cerebral ischemia.Conclusion Qixian Tongluo Formula can significantly improve the functional independence level of patients with kidney deficiency and blood stasis syndrome in the recovery period of paralysis after cerebral infarction,offering a safe and effective treatment option for these patients;There were a large number of miRNAs in Qixian Tongluo decoction,some of which could cross-kingdom transferred into the human blood circulation,and promote the recovery of motor function in patients with cerebral infarction through multi-target,multi link and multi pathway gene network regulation.This study provides a new idea for subsequent clinical and basic research.

Thyrotoxic periodic paralysis(TPP) is a rare but potentially life-threatening complication of thyrotoxicosis. TPP secondary to thyrotoxicosis factitia(TF) is exceptionally uncommon. Here, we report the case of a 31-year-old female who developed TF and subsequent TPP after taking laxatives containing unknown ingredients. The patient presented with acute onset of quadriplegia. Laboratory investigations revealed severe hypokalemia(serum potassium 1.47mmol/L), thyrotoxicosis[thyroid stimulating hormone(TSH)<0.005 mIU/L, free thyroxine(FT 4) 30.84 pmol/L, free triiodothyronine(FT 3) 7.71 pmol/L], and a decreased thyroglobulin level(3.08 ng/mL). The patient′s symptoms resolved rapidly following potassium supplementation, and thyroid function gradually normalized after discontinuation of the suspected medication. This case highlights the importance of considering TF in the differential diagnosis of TPP, particularly in patients with a history of unknown medication use. It also underscores the diagnostic value of thyroglobulin measurement in identifying TF and outlines clinical strategies for the management of TF-induced TPP.

Objectives:To investigate the expression and clinical prognostic implication of secreted frizzled-related protein 4(SFRP4)in the peripheral blood of patients with dilated cardiomyopathy(DCM)and its.Methods:A total of 259 consecutive patients diagnosed with DCM who were admitted to the Cardiac Center of Zhongshan Hospital,Fudan University,from January 2017 to January 2019 were selected for the DCM group.Additionally,84 individuals who underwent health examinations and echocardiography at our hospital during this period,confirmed to be free of cardiovascular diseases,were selected as the control group.Peripheral serum samples were collected from both groups,and serum SFRP4 levels were measured using enzyme-linked immunosorbent assay(ELISA).The correlation between SFRP4 levels and DCM severity,as well as its predictive value for DCM prognosis,were analyzed.Results:Compared to the control group,the serum SFRP4 levels in the DCM group were significantly elevated([28.54±10.25]ng/ml vs.[52.70±19.74]ng/ml,P<0.05).The DCM group was randomly divided into a training set and a validation set in a 2:1 ratio.Multivariate logistic regression analysis in the training set revealed that serum SFRP4 levels were independently associated with all-cause mortality in DCM patients(OR=1.06,95% CI:1.03-1.10,P<0.001).We further evaluated the model's predictive performance with the receiver operating characteristic(ROC)curves(area under curve>0.8),calibration curves,and decision curve analysis,results indicated that the predictive model containing serum SFRP4 levels showed good performance on predicting all-cause mortality in DCM patients.Kaplan-Meier survival curve analysis demonstrated that during a median follow-up of 33.5(11.0,49.0)months,DCM patients with high peripheral blood SFRP4 levels(≥75th percentile)had a significantly higher incidence of all-cause mortality compared to those with low levels(<75th percentile)(28.81% vs.16.57%,P=0.02).Conclusions:The level of SFRP4 in the peripheral blood of DCM patients is significantly elevated,and peripheral serum SFRP4 levels have potential prognostic value for predicting the all-cause mortality in DCM patients.